Skip to main content
. 2026 Oct 15;55(7):3033–3058. doi: 10.1007/s10508-026-03548-5

Table 2.

Quantitative cohort: Country of residence, marital status, and cancer history

Total
(N = 103)
RRBSO
(n = 17)
RRBSO + ETBSOc
(n = 26)
SM
(n = 22)
AMC
(n = 38)
n % n % n % n %
Country of residence
Canada 16 94.12 25 96.15 20 90.91 30 78.95
Othera 1b 5.88 1 3.85 2 9.09 8 21.05
Marital status
Never married 1 5.88 0 0 3 13.64 6 15.79
Separated 0 0 2 7.69 3 13.64 2 5.26
Common law 3 17.65 2 7.69 2 9.09 3 7.89
Divorced 0 0 1 3.85 1 4.55 1 2.63
Married 13 76.47 21 80.77 11 50.00 26 68.42
Widowed 0 0 0 0 2 9.09 0 0
Cancer history
BC Diagnosis 5 29.41 2 7.69 0 0 0 0
BC Treatment: Surgery 2 11.76 1 3.85 0 0 0 0
BC Treatment: Surgery and chemotherapy 1 5.88 1 3.85 0 0 0 0
BC Treatment: Surgery, chemotherapy, and radiation 2 11.76 0 0 0 0 0 0
Other cancer diagnosis 2 11.76 1 3.85 2 9.09 2 5.26
Other cancer treatment: Surgery 2 11.76 1 3.85 1 4.55 2 5.26
Other cancer treatment: Surgery and radiation 0 0 0 0 1 4.55 0 0

RRBSO, risk-reducing bilateral salpingo-oophorectomy; RRBSO + ETBSO, women with RRBSO taking estradiol therapy (ETBSO); SM, spontaneous menopause; AMC, age-matched controls; BC, breast cancer

aWestern, English-speaking country of residence outside of Canada

bParticipant did not report their country of residence

cTaking concurrent androgel (n = 2) and tibolone (n = 1)